PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant

Next Previous
Trial Profile

PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Busulfan (Primary) ; Fludarabine (Primary) ; Antithymocyte globulin
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Therapeutic Use
  • Acronyms FLUBUTBI

    • Most Recent Events

    • 08 Aug 2017 The study is now recruiting subjects.
    • 08 Aug 2017 Planned End Date changed from 1 Dec 2015 to 1 Aug 2018.
    • 08 Aug 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top